Management of Severe Aortic Stenosis in Pregnancy

Risk Assessment & Monitoring

• Severe aortic stenosis (AS) poorly tolerates pregnancy because the 30‑50 % rise in cardiac output, increased heart rate, and reduced systemic vascular resistance cannot be matched by the stenotic valve, leading to rapid decompensation. 1, 2, 3
• Immediate multidisciplinary care at a tertiary center with a dedicated Heart Valve Team (maternal‑fetal medicine, cardiology, cardiac surgery, cardiac anesthesiology) is essential to monitor hemodynamics and fetal status. 1, 2, 3

Diagnostic Evaluation

• Comprehensive transthoracic echocardiography must be performed to quantify valve area, trans‑valvular gradients, left‑ventricular function, and pulmonary pressures. 1, 2
• Detailed assessment of aortic root dimensions is required because bicuspid aortic valve—common in young women—carries a risk of aortopathy, dilation, and dissection during pregnancy. 1, 3, 4
• Systematic evaluation of functional capacity and symptoms (dyspnea, angina, syncope, heart‑failure signs) guides urgency of intervention. 1, 2

Medical Management

• The primary goal is to maintain hemodynamic stability through careful medical optimization while avoiding destabilizing therapies. 5
• Strict activity restriction and bed rest for symptomatic patients help limit cardiac workload. 5
• Clinical and echocardiographic follow‑up should be performed at least monthly (or bimonthly) to detect clinical deterioration, worsening valve hemodynamics, or left‑ventricular dysfunction. 4

Intervention Thresholds

Percutaneous Balloon Aortic Valvuloplasty (BAV)

• BAV is reserved as a life‑saving measure only for patients with severe, refractory heart‑failure symptoms despite maximal medical therapy. 5
• Indications include:
• BAV must be performed in highly experienced centers with expertise in structural cardiac interventions and high‑risk obstetrics; radiation exposure should be minimized using abdominal shielding and limited fluoroscopy time. 5
• The procedure provides only palliative benefit and does not replace the need for definitive valve replacement after delivery. 5

Surgical Valve Replacement (Rare)

• Open cardiac surgery with cardiopulmonary bypass carries substantial fetal risk (≈20‑30 % fetal mortality) and is considered only when maternal survival is otherwise untenable, preferably in the second trimester.

Delivery Planning

• Vaginal delivery with epidural anesthesia is preferred for stable patients; cesarean section is reserved for obstetric indications. 5
• Delivery should be scheduled at 36‑38 weeks in a tertiary center equipped with immediate cardiac‑surgical backup. 5
• Epidural anesthesia is recommended to blunt hemodynamic fluctuations and prevent tachycardia; general anesthesia should be avoided when possible. 5
• Invasive hemodynamic monitoring (arterial line, consider pulmonary‑artery catheter) during labor and delivery enhances safety. 5

Pitfalls to Avoid

• Do not assume stability—severe AS can decompensate rapidly, especially in the third trimester. 1, 2, 3
• Do not delay transfer to a tertiary center; specialized expertise is critical. 1, 2
• Prophylactic BAV in asymptomatic or mildly symptomatic patients is contraindicated because risks outweigh benefits. 5

Post‑partum Management

• Definitive aortic valve replacement should be scheduled 3‑6 months after delivery, after maternal recovery and completion of breastfeeding if desired. 1, 2
• Decision between mechanical and bioprosthetic prostheses must balance lifelong anticoagulation requirements (mechanical) against limited durability of bioprosthetic valves in young patients. 1, 2

Management of Severe Aortic Stenosis

Diagnostic Confirmation

• The American College of Cardiology recommends confirming severe aortic stenosis using echocardiographic criteria: aortic valve area ≤1.0 cm², peak velocity ≥4 m/sec, or mean gradient ≥40 mmHg 6, 7
• Assess for specific symptoms including exertional dyspnea, angina, syncope, or dizziness, and evaluate exercise capacity limitations below age and sex-specific predicted metabolic equivalents 6
• In low-flow, low-gradient AS, perform low-dose dobutamine stress echocardiography to distinguish true-severe from pseudo-severe stenosis and evaluate for contractile or flow reserve 8, 6, 9

Risk Stratification

• Calculate surgical risk using the STS-PROM score, with categories including low risk (STS-PROM <3%), intermediate risk (STS-PROM 4-8%), high risk (STS-PROM >8%), and prohibitive risk 6
• The European Society of Cardiology recommends considering patient anatomy, frailty, and patient preference when determining the approach for intermediate-risk patients 6

Management Algorithm for Symptomatic Patients

• For symptomatic severe AS, proceed immediately with valve replacement, with the choice between TAVR and SAVR determined by surgical risk stratification using the STS-PROM score and Heart Team assessment 7, 9
• The American Heart Association recommends TAVR as a reasonable alternative to SAVR for high-surgical-risk patients 6
• For prohibitive surgical risk, TAVR is the recommended approach if predicted post-TAVR survival >1 year 8, 6

Management Algorithm for Asymptomatic Patients

• The American College of Cardiology recommends watchful waiting with regular clinical and echocardiographic follow-up every 6-12 months for most asymptomatic patients with normal left ventricular function 6, 7
• Proceed with valve replacement in asymptomatic patients if left ventricular ejection fraction <50%, very severe AS, abnormal exercise stress test, rapid progression of stenosis, or undergoing cardiac surgery for another indication 6, 7

Medical Management Principles

• Maintain adequate preload and avoid excessive diuresis while awaiting valve replacement or in patients not candidates for intervention 7
• Control heart rate to maintain adequate diastolic filling time and avoid tachycardia 7
• Avoid vasodilators and positive inotropes 9
• Control blood pressure and other cardiovascular risk factors 9
• Do not use statins to prevent progression of AS 9

Special Populations

• For low-flow, low-gradient AS with reduced LVEF, perform dobutamine stress echocardiography to confirm true stenosis severity 8, 6, 9
• If mean gradient is >40 mmHg with dobutamine, there is theoretically no lower LVEF limit for aortic valve replacement in symptomatic patients 8

Heart Team Approach

• All complex decisions should involve a multidisciplinary Heart Team comprising cardiac surgery, interventional cardiology, cardiac imaging, anesthesiology, and geriatrics expertise 6

Key TAVR Outcomes and Complications

• TAVR demonstrates sustained mortality benefit at 2 years compared to medical therapy in inoperable patients, with improved functional status and reduced rehospitalization 6
• TAVR-specific complications include paravalvular aortic regurgitation 8, permanent pacemaker requirement 8, and acute kidney injury 9